Status:
COMPLETED
A Study to Understand the Treatment Patterns and Patients and Their Clinical Outcomes Who Are Taking Palbociclib in a Real Life Setting in Israel.
Lead Sponsor:
Pfizer
Conditions:
Metastatic Breast Cancer
Eligibility:
All Genders
18-99 years
Brief Summary
The purpose of this study is to understand the treatment patterns, patients and their clinical outcomes in a real life setting in Israel. This study was done in adult breast cancer patients who have s...
Eligibility Criteria
Inclusion
- A diagnosis of metastatic breast cancer, based on the National/MHS cancer registry.
- Newly diagnosed metastatic breast cancer patients and newly treated with palbociclib within 6 months of diagnosis, in any line of treatment in the metastatic setting.
- Available data on palbociclib treatment for at least 6 months.
- Continuous healthcare plan enrolment in MHS for at least one year before index date.
Exclusion
- Patients that initiated HER2 inhibitors.
Key Trial Info
Start Date :
December 6 2020
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
November 30 2022
Estimated Enrollment :
559 Patients enrolled
Trial Details
Trial ID
NCT04671615
Start Date
December 6 2020
End Date
November 30 2022
Last Update
December 10 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Pharmaceuticals Israel Ltd.
Herzliya Pituah, Israel, 4672509